Malaga Cove Capital LLC decreased its stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 0.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 84,241 shares of the biopharmaceutical company’s stock after selling 28 shares during the period. Malaga Cove Capital LLC’s holdings in Sucampo Pharmaceuticals were worth $882,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $555,000. State Street Corp boosted its stake in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock valued at $7,882,000 after buying an additional 143,906 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock valued at $21,130,000 after buying an additional 103,986 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Sucampo Pharmaceuticals during the fourth quarter valued at about $115,000. Finally, Bank of Montreal Can boosted its stake in shares of Sucampo Pharmaceuticals by 22.9% in the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 4,615 shares in the last quarter. 56.98% of the stock is currently owned by institutional investors and hedge funds.

Sucampo Pharmaceuticals, Inc. (SCMP) traded up 0.46% during mid-day trading on Friday, hitting $10.95. 217,728 shares of the company were exchanged. The stock has a market cap of $508.78 million, a price-to-earnings ratio of 18.25 and a beta of 1.46. Sucampo Pharmaceuticals, Inc. has a 12 month low of $9.30 and a 12 month high of $17.55. The firm has a 50 day moving average price of $10.40 and a 200 day moving average price of $10.89.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.28 by $0.05. The company had revenue of $56.30 million for the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The business’s revenue was up 19.3% on a year-over-year basis. During the same period last year, the firm posted $0.21 earnings per share. Analysts anticipate that Sucampo Pharmaceuticals, Inc. will post $1.04 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Malaga Cove Capital LLC Lowers Stake in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/07/22/malaga-cove-capital-llc-lowers-stake-in-sucampo-pharmaceuticals-inc-nasdaqscmp.html.

SCMP has been the topic of several research reports. Maxim Group reissued a “buy” rating and set a $21.00 price target (up previously from $19.00) on shares of Sucampo Pharmaceuticals in a research report on Monday, April 3rd. Mizuho reissued a “buy” rating and set a $14.00 price target on shares of Sucampo Pharmaceuticals in a research report on Tuesday, April 4th. Jefferies Group LLC set a $13.00 price target on shares of Sucampo Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, April 20th. ValuEngine cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Sucampo Pharmaceuticals has an average rating of “Buy” and an average price target of $17.00.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.